RxREVU raises $3M for its medication optimization solution

RxREVU

RxREVU has raised $3 million from Summation Health Ventures and NueCura Partners, bringing its total funding to date to $4.76 million, according to CrunchBase.

The company has developed a next generation prescription decision support at the point of care to help large health systems reduce costs and improve outcomes. RxREVU’s service provides physicians with better data at the point of care, including patient cost, adherence, and efficacy analytics, along with less expensive therapeutic alternatives and hard-wired payer clinical protocols. This, the company claims, offers more informed and consistent prescribing to health systems that are drowning in high prescription drug costs.

In addition, the RxREVU platform provides a way for health systems to distribute their clinical protocols to the point of care, to help align their physicians with national guidelines and cost-effective prescribing protocols.

“We’re extremely pleased to have Summation Health Ventures as an investor in our company. They represent world renowned health systems, and are exactly the kind of forward-thinking innovators that we want to work with,” RxREVU CEO Carm Huntress said in a statement, adding “and NeuCura Partners is a physician founded investment group that further validates the position of our product and our mission.”

In 2013, RxREVU announced that it has passed 2,000 cost-saving recommendations.